ETF overview
ProShares Trust - ProShares Ultra Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. It invests through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology, drugs manufacturer, diagnostic development and life sciences sectors. It uses derivatives such as swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track 2x the daily performance of the Nasdaq Biotechnology Index, by using full replication technique. ProShares Trust - ProShares Ultra Nasdaq Biotechnology was formed on April 7, 2010 and is domiciled in the United States.
Fund facts
- Leverage
- 2x daily
- Expense ratio
- 1.17%
- Fund assets
- 96.28M USD (all share classes)
- Issuer
- ProShares
- Inception date
- Apr 7, 2010
- Number of holdings
- 255
Holdings (255)
| Name | Ticker | Exposure |
|---|---|---|
| NASDAQ Biotechnology Index SWAP Societe Generale | - | |
| NASDAQ Biotechnology Index SWAP Goldman Sachs International | - | |
| NASDAQ Bio Index SWAP BNP Paribas | - | |
| NASDAQ Biotechnology Index SWAP Citibank NA | - | |
| NASDAQ Biotechnology Index SWAP UBS AG | - | |
| NASDAQ Biotechnology Index SWAP Bank of America NA | - | |
| PROSHARES GENIUS MNY MKT ETF | IQMM | 19.24% |
| GILEAD SCIENCES INC | GILD | 5.66% |
| AMGEN INC | AMGN | 5.34% |
| VERTEX PHARMACEUTICALS INC | VRTX | 4.87% |
| and 242 more | ||
This is a leveraged or inverse fund. Exposure is each position's value as a share of the fund's net assets, so swaps and futures can take it above 100% or below 0%. Swaps and futures the fund reports at no value show no exposure. Cash held as collateral is not listed.
Historical returns do not guarantee future returns. This is not investment advice.
- Leverage
- 2x daily
- Expense ratio
- 1.17%
- Fund assets
- 96.28M USD (all share classes)
- Issuer
- ProShares
- Inception date
- Apr 7, 2010
- Number of holdings
- 255
| Name | Ticker | Exposure |
|---|---|---|
| NASDAQ Biotechnology Index SWAP Societe Generale | - | |
| NASDAQ Biotechnology Index SWAP Goldman Sachs International | - | |
| NASDAQ Bio Index SWAP BNP Paribas | - | |
| NASDAQ Biotechnology Index SWAP Citibank NA | - | |
| NASDAQ Biotechnology Index SWAP UBS AG | - | |
| NASDAQ Biotechnology Index SWAP Bank of America NA | - | |
| PROSHARES GENIUS MNY MKT ETF | IQMM | 19.24% |
| GILEAD SCIENCES INC | GILD | 5.66% |
| AMGEN INC | AMGN | 5.34% |
| VERTEX PHARMACEUTICALS INC | VRTX | 4.87% |
| and 242 more | ||
This is a leveraged or inverse fund. Exposure is each position's value as a share of the fund's net assets, so swaps and futures can take it above 100% or below 0%. Swaps and futures the fund reports at no value show no exposure. Cash held as collateral is not listed.
ProShares Trust - ProShares Ultra Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. It invests through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology, drugs manufacturer, diagnostic development and life sciences sectors. It uses derivatives such as swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track 2x the daily performance of the Nasdaq Biotechnology Index, by using full replication technique. ProShares Trust - ProShares Ultra Nasdaq Biotechnology was formed on April 7, 2010 and is domiciled in the United States.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free